US prostate cancer market diagnostics and therapeutics are forecast to augment at a CAGR of 10.4% during the forecast period. The major factors for the growth of the market include the high prevalence of prostate cancer in the country. As per the World Health Organization, in US prostate cancer is the most prevalent cancer among men. Around 212,000 new cases of prostate cancer have been registered in 2018 in the country which is around 18.5% of the overall cancer cases. Moreover, it is the sixth-highest reason for mortality in the country due to cancer. In 2018, around 29,000 mortalities were registered in the country. According to the American Cancer Society, nearly $12 billion in treatment is spent every year for prostate cancer treatment. In addition, the adoption of innovative technologies for the diagnosis of prostate cancer such as biomarkers and the adoption of personalized medicine for treatment is expected to fuel the market.

Request a free sample of our report on US Prostate Cancer Market https://www.omrglobal.com/request-sample/us-prostate-cancer-diagnostic-therapeutic-market

US prostate cancer diagnostic market is segmented on the basis of diagnostic techniques and therapeutics. By diagnostic technique, the market is further divided into prostate-specific antigen test, digital rectal examination, prostate biopsy, imaging techniques. Prostate biopsy is expected to hold a significant market share during the forecast period. By therapeutics, the market is further divided into hormonal therapy, chemotherapy, immunotherapy, radiation therapy, targeted therapy, surgery. During the forecast period, chemotherapy is expected will hold a major market share in the country.

A full Report of US Prostate Cancer Market is Available at: https://www.omrglobal.com/industry-reports/us-prostate-cancer-diagnostic-therapeutic-market

The companies which are contributing significantly in the market include Abbott Laboratories, AbbVie Products, LLC, Amgen Inc., Ferring Pharmaceuticals Inc., Johnson & Johnson, Siemens Healthcare AG, Amgen Inc., AstraZeneca PLC, Bayer AG, Endo Pharmaceuticals Inc., Bristol-Myers Squibb Co., GlaxoSmithKline PLC, Johnson & Johnson, Pfizer Inc., and others. The market players are considerably contributing to the market growth by the adoption of various growth strategies including new product launch, merger, and acquisition, collaborations with government, and technological advancements to stay competitive in the market.

US Prostate Cancer Market Segmentation

By Diagnostic Techniques

• Prostate-Specific Antigen Test (PSA)
• Digital Rectal Examination
• Prostate Biopsy
• Imaging Techniques

By Therapeutics

• Hormonal Therapy
• Chemotherapy
• Immunotherapy
• Radiation Therapy
• Targeted Therapy
• Surgery

Regional Analysis

• United States
• Canada

Company Profiles

• Abbott Laboratories
• AbbVie Products, LLC
• Amgen Inc.
• AstraZeneca PLC
• Bavarian Nordic A/S
• Bayer AG
• Bristol-Myers Squibb Co.
• Endo Pharmaceuticals Inc.
• Ferring Pharmaceuticals Inc.
• GlaxoSmithKline PLC
• Johnson & Johnson
• Pfizer Inc.
• Siemens Healthcare AG
• Decipher Biosciences, Inc.
• Nanostics Inc.

For More Customized Data, Request for Report Customization https://www.omrglobal.com/report-customization/us-prostate-cancer-diagnostic-therapeutic-market

About Orion Market Research

Orion Market Research (OMR) is a market research and consulting company known for its crisp and concise reports. The company is equipped with an experienced team of analysts and consultants. OMR offers quality syndicated research reports, customized research reports, consulting and other research-based services.

For More Information, Visit https://www.omrglobal.com/
Media Contact:

Company Name: Orion Market Research
Contact Person: Mr. AnuragTiwari
Email: [email protected]
Contact no: +1 646-755-7667, +91 780-304-0404